ADRP/ADFP and Mal1 expression are increased in macrophages treated with TLR agonists
- 31 March 2010
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 209 (1) , 81-88
Abstract
No abstract availableKeywords
Funding Information
- Research Service of the Department of Veterans Affairs, National Institutes of Health Grant (5R01HD029706)
This publication has 40 references indexed in Scilit:
- Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-α production via down-regulation of MyD88 expressionInnate Immunity, 2009
- TLR4 links innate immunity and fatty acid–induced insulin resistanceJournal of Clinical Investigation, 2006
- Lipid Droplets Gain PAT Family Proteins by Interaction with Specialized Plasma Membrane DomainsJournal of Biological Chemistry, 2005
- Combined Adipocyte-Macrophage Fatty Acid–Binding Protein Deficiency Improves Metabolism, Atherosclerosis, and Survival in Apolipoprotein E–Deficient MiceCirculation, 2004
- Inferences, questions and possibilities in Toll-like receptor signallingNature, 2004
- Lipopolysaccharide Down Regulates Both Scavenger Receptor B1 and ATP Binding Cassette Transporter A1 in RAW CellsInfection and Immunity, 2002
- Infection and AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Molecular mechanisms of NF-κB activation induced by bacterial lipopolysaccharide through Toll-like receptorsInnate Immunity, 2000
- PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in VivoJournal of Biological Chemistry, 1995
- SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1FEBS Letters, 1995